Abstract

Alzheimer’s disease (AD) is the most common form of dementia and currently has no cure. This study will use the novel and promising technique of magnetoencephalographic imaging (MEG), in patients with AD, to characterize abnormal neural firing associated with AD pathophysiological processes and with progressive cognitive deficits. We aim to identify potential new biomarkers to help early detection and monitor the disease progression as well as therapeutic efficacy in clinical trials. Our findings will provide a better physiological model incorporating neuroinflammation and network deficits in patients with AD, and will also generate new insights on neurobehavioral associations, which are crucial for designing and developing disease-modifying strategies to counter this debilitating disease.